Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15082655 | 0.89 | CA2 (0.35) | CA2PPARDKDM4EMMP2THRB | |
| SCHEMBL13113828 | 0.89 | KDM4E (0.45) | CA2PPARDKDM4EMMP2THRB | |
| SCHEMBL28299764 | 0.80 | PPARD (0.41) | CA2PPARDKDM4EMMP2THRB | |
| SCHEMBL13374689 | 0.78 | CA2 (0.35) | CA2PPARDKDM4EMMP2THRB | |
| SCHEMBL3364605 | 0.77 | — | — | |
| SCHEMBL12197583 | 0.76 | PPARD (0.43) | CA2PPARDFDPSCYP2C19SMN1; SMN2 | |
| SCHEMBL16286118 | 0.71 | — | — | |
| SCHEMBL2045368 | 0.71 | — | — | |
| SCHEMBL12568973 | 0.71 | — | — | |
| SCHEMBL14870920 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288545-B2 | Reactive pyrophosphoric and bisphosphonic acid derivatives and methods of their use | GLSYNTHESIS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20090299048-A1 | REACTIVE PYROPHOSPHORIC AND BISPHOSPHONIC ACID DERIVATIVES AND METHODS OF THEIR USE | GLSYNTHESIS INC (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299048-A1 | REACTIVE PYROPHOSPHORIC AND BISPHOSPHONIC ACID DERIVATIVES AND METHODS OF THEIR USE | PPA1, PPIP5K2, ITPA | CA2 843/4885PPARD 2262/4885KDM4E 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.